European Journal of Nuclear Medicine and Molecular ImagingPharmacology & ToxicologyPeer-reviewed journal article
Exploring the PET in vivo generator 134Ce as a theranostic match for 225Ac
David BaueriD, Roberto De GregorioiD, Edwin C. PrattiD, Abram BelliD, Alexa L. MicheliD, Jason Stuart LewisiD
Abstract
PurposeThe radionuclide pair cerium-134/lanthanum-134 (134Ce/134La) was recently proposed as a suitable diagnostic counterpart for the therapeutic alpha-emitter actinium-225 (225Ac). The unique properties of 134Ce offer perspectives for developing innovative in vivo investigations not possible with 225Ac. In this work, 225Ac- and 134Ce-labeled tracers were directly compared using internalizing and slow-internalizing cancer models to evaluate their in vivo comparability, progeny meandering, and potential as a matched theranostic pair for clinical translation. Despite being an excellent chemical match, 134Ce/134La has limitations to the setting of quantitative positron emission tomography imaging. MethodsThe precursor PSMA-617 and a macropa-based tetrazine-conjugate (mcp-PEG8-Tz) were radiolabelled with 225Ac or 134Ce and compared in vitro and in vivo using standard (radio)chemical methods. Employing biodistribution studies and positron emission tomography (PET) imaging in athymic nude mice, the radiolabelled PSMA-617 tracers were evaluated in a PC3/PIP (PC3 engineered to express a high level of prostate-specific membrane antigen) prostate cancer mouse model. The 225Ac and 134Ce-labeled mcp-PEG8-Tz were investigated in a BxPC-3 pancreatic tumour model harnessing the pretargeting strategy based on a trans-cyclooctene-modified 5B1 monoclonal antibody. ResultsIn vitro and in vivo studies with both 225Ac and 134Ce-labelled tracers led to comparable results, confirming the matching pharmacokinetics of this theranostic pair. However, PET imaging of the 134Ce-labelled precursors indicated that quantification is highly dependent on tracer internalization due to the redistribution of 134Ces PET-compatible daughter 134La. Consequently, radiotracers based on internalizing vectors like PSMA-617 are suited for this theranostic pair, while slow-internalizing 225Ac-labelled tracers are not quantitatively represented by 134Ce PET imaging. ConclusionWhen employing slow-internalizing vectors, 134Ce might not be an ideal match for 225Ac due to the underestimation of tumour uptake caused by the in vivo redistribution of 134La. However, this same characteristic makes it possible to estimate the redistribution of 225Acs progeny noninvasively. In future studies, this unique PET in vivo generator will further be harnessed to study tracer internalization, trafficking of receptors, and the progression of the tumour microenvironment. TOC Graphic O_FIG O_LINKSMALLFIG WIDTH=200 HEIGHT=167 SRC="FIGDIR/small/591165v1_ufig1.gif" ALT="Figure 1"> View larger version (61K): org.highwire.dtl.DTLVardef@ca3cb6org.highwire.dtl.DTLVardef@157eac6org.highwire.dtl.DTLVardef@f6ac6dorg.highwire.dtl.DTLVardef@b24d87_HPS_FORMAT_FIGEXP M_FIG C_FIG Redistribution of progeny. Investigating the 225Ac and 134Ce decay chain. This figure was created with BioRender.
- organism: mouse
- assay: imaging
- research focus: host-pathogen & immune response
- approach: experimental assay
- Citations
- 14
- FWCI
- 2.90
- Field percentile
- top 8%
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- In vivo Quantitative Tomography of 225Ac Daughters in a Prostate Cancer Mouse Model with a Compton Camera
Biswajit Das, Anil P. Bidkar, … J. Caravaca Rodríguez·bioRxiv·Sep 22, 2026
- -Labeled PARP-1 PET Imaging of PSMA Targeted Alpha Particle Radiotherapy Response
H. Zhang, D. Abou, … D. L. Thorek·bioRxiv·Mar 16, 2022
- A New Labelling Method of 99mTc-PSMA-HBED-CC
Benchamat Phromphao, Shuichi Shiratori·World Journal of Nuclear MedicinePeer-reviewed·Jun 26, 2025
- Treatment of prostate cancer with CD46 targeted 225Ac alpha particle radioimmunotherapy
A. P. Bidkar, S. Wang, … R. R. Flavell·bioRxiv·Oct 13, 2022
- Radiolabeling of PSMA-617 with 89Zr: A Novel Use of DMSO for Radiochemical Yield Enhancement and Preliminary Small-Animal PET Results
R. Imura, A. N. Ozeki, … Y. Kumakura·bioRxiv·Jun 28, 2021
- PSA-targeted Alpha-, Beta- and Positron Emitting Immuno-Theranostics in Murine Prostate Cancer Models and Non-Human Primates
D. Veach, C. M. Storey, … D. Ulmert·bioRxiv·Sep 11, 2020